ACM
EBACU

Atalaya Capital Management’s European Biotech Acquisition Corp. Units EBACU Stock Holding History

Atalaya Capital Management’s Portfolio EBACU Stock Details EBACU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40,000
Closed -$402K – 383
2021
Q1 		$402K Buy
+40,000
New +$400K 0.08% 142

Other funds holding EBACU

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.27% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
ACA
Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Atalaya Capital Management's EBACU Position: Q2 2021 in Review

Atalaya Capital Management sold out of European Biotech Acquisition Corp. Units (EBACU) in Q2 2021, closing a stake of 40,000 shares — an estimated $402K sold.

Atalaya Capital Management first reported a position in EBACU in Q1 2021 and held it in 1 quarter. The position peaked at $402K in Q1 2021. 37 funds tracked by Wall St. Rank hold EBACU as of Q2 2021.

  • Atalaya Capital Management reported no remaining European Biotech Acquisition Corp. Units position as of Q2 2021 after selling out during the quarter.
  • Atalaya Capital Management sold 40,000 European Biotech Acquisition Corp. Units shares in Q2 2021, an estimated $402K.
  • Atalaya Capital Management first reported a position in European Biotech Acquisition Corp. Units in Q1 2021 and held it in 1 quarter.
  • Atalaya Capital Management's European Biotech Acquisition Corp. Units position peaked at $402K in Q1 2021.
  • 37 funds tracked by Wall St. Rank held European Biotech Acquisition Corp. Units as of Q2 2021.

Based on Atalaya Capital Management's 13F filing for Q2 2021, filed 12 Aug 2021.